logo

For the Inventor, By the Inventor

Dublin, Ireland

Nogra Pharma Limited


USPTO Granted Patents = 53

% Expired Patents = 41.5



Trademarks = 13

Forward Citations = 572

Loading Chart...
Loading Chart...

15 inventors (with patents filed for the assignee):

goldMedal Francesca Viti (29 out of 29 patents)

silverMedal Sergio Baroni (26 out of 46 patents)

bronzeMedal Salvatore Bellinvia (25 out of 27 patents)

4.  Giovanni Monteleone (20 out of 23 patents)

5.  Giancarlo Naccari (7 out of 10 patents)

6.  Salvatore Demartis (5 out of 5 patents)

7.  Marie McNulty (3 out of 3 patents)

8.  Alice Tomei (2 out of 6 patents)

9.  Peter Buchwald (2 out of 4 patents)

10.  Daan Hommes (2 out of 2 patents)

11.  Auke Verhaar (2 out of 2 patents)

12.  Gijs Van Den Brink (2 out of 2 patents)

13.  Luca Inverardi (2 out of 9 patents)

14.  Antonello Pileggi (2 out of 5 patents)

15.  Camillo D Ricordi (2 out of 26 patents)


Core Competencies:
Fibrosis Treatment
IL-34 Antisense Agents
Aryl Receptor Modulators
SMAD7 Inhibition
Inflammatory Bowel Disease
Diabetes Treatment
Hair Related Conditions
T-Cell Modulation
Colorectal Cancer Treatment
Lactose Intolerance
PPAR Receptor Compounds
Antisense Oligonucleotides

53 patents:

1. 12577256 - ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME (2026-03-17),
2. 12509416 - Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof (2025-12-30),
3. 12291494 - Methods of treating fibrosis (2025-05-06),
4. 12071623 - IL-34 antisense agents and methods of using same (2024-08-27),
5. 12012418 - Aryl receptor modulators and methods of making and using the same (2024-06-18),
6. 11905232 - Process of making 3-(4′-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof (2024-02-20),
7. 11753365 - Methods of treating fibrosis (2023-09-12),
8. 11427600 - Aryl receptor modulators and methods of making and using the same (2022-08-30),
9. 11162097 - Methods of treating intestinal fibrosis using SMAD7 inhibition (2021-11-02),
10. 11046641 - Methods of treating fibrosis (2021-06-29),
11. 10959970 - Methods of treating hair related conditions (2021-03-30),
12. 10738309 - Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field (2020-08-11),
13. 10633660 - Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field (2020-04-28),
14. 10562883 - Heterocycles capable of modulating T-cell responses, and methods of using same (2020-02-18),
15. 10473669 - Methods for treating inflammatory bowel disease (2019-11-12),
Nogra Pharma Limited is a leading pharmaceutical company specializing in the development and production of innovative healthcare solutions. With a strong dedication to research and development, Nogra Pharma is committed to providing high-quality medications and medical products to improve the well-being of people worldwide. Our cutting-edge facilities, state-of-the-art technology, and highly skilled professionals enable us to offer a wide range of products across various therapeutic areas. Through continuous innovation and adherence to strict quality standards, Nogra Pharma aims to make a positive impact on global healthcare.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Nogra Pharma Limited
53 Patents

#36 in Dublin

#62 in Ireland

#13,309 in the World

Dublin, IE
Dublin, Ireland

Nogra Pharma Limited

Forward Citations = 572

15 inventors:

goldMedal Francesca Viti (29 out of 29 patents)

silverMedal Sergio Baroni (26 out of 46 patents)

bronzeMedal Salvatore Bellinvia (25 out of 27 patents)

4.  Giovanni Monteleone (20 out of 23 patents)

5.  Giancarlo Naccari (7 out of 10 patents)

Please report any incorrect information to [email protected]
Loading…